Out-licensing

A method and composition for inhibiting or treating symptoms of inflammatory demyelination or inflammation associated with autoimmune disorders.

The invention is a method and composition for inhibiting or treating symptoms of inflammatory demyelination or inflammation associated with autoimmune disorders. This is accomplished by administering recombinant E-selectin protein intranasally and resulting in E selectin-specific regulatory T-cells. These regulatory T-cells suppress activation of blood vessels where E-selectin is normally expressed by the localized production of immunosuppressive cytokines, modulating the actions of otherwise pro-inflammatory T cells that can aberrantly cause demyelination of neurons, which leads to diseases like MS.

 

Applications:

In addition to MS, potentially effective in treating other autoimmune disorders such as rheumatoid arthritis, type 1 diabetes, psoriasis, and those that affect blood vessels.

 

Development Status:

In vitro and in vivo data are available.

 

U.S. Provisional Application No. 60/828,735 filed 09 Oct 2006 (HHS Reference No. E-153-2005/0-US-01)

PCT Application No. PCT/2007/021682 filed 09 Oct 2007 (HHS Reference No. E-153-2005/2-PCT-02)

Inventors:

Jacqueline Shukaliak-Quandt et al. (NINDS)

 

 

 

Licensees Sought:

Available for non-exclusive or exclusive licensing.